The Challenge of Offering Long-Acting Antipsychotic Therapies: A Preliminary Discourse Analysis of Psychiatrist Recommendations for Injectable Therapy to Patients With Schizophrenia

被引:45
|
作者
Weiden, Peter J. [1 ]
Roma, Rebecca S. [2 ]
Velligan, Dawn I. [3 ]
Alphs, Larry [4 ]
DiChiara, Matthew [5 ]
Davidson, Brad [5 ]
机构
[1] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Schizophrenia & Related Disorders, San Antonio, TX 78229 USA
[3] Mercy Behav Hlth Pittsburgh, Community Treatment Team, Pittsburgh, PA USA
[4] Janssen Sci Affairs, Therapeut Area Lead Psychiat, Titusville, NJ USA
[5] Ogilvy CommonHlth Behav Insights, Parsippany, NJ USA
关键词
Antipsychotics; Delivery of Care; Schizophrenia; SHARED DECISION-MAKING; IN-OFFICE; PERSPECTIVES; ADHERENCE; DEPOT; COMMUNICATION; PERCEPTIONS; STRATEGIES; ATTITUDES; PROVIDER;
D O I
10.4088/JCP.13m08946
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: To characterize patterns of communication in the offer of long-acting injectable (LAI) antipsychotic medication made by psychiatrists to patients with schizophrenia by (1) examining the style and content of their interaction and (2) determining how these may have driven the ultimate response to recommendations for LAI therapy. Method: This was an observational study conducted at 10 community mental health centers in 3 waves from July 2010 to May 2011. The final dataset for discourse analysis was 33 recorded conversations in which a psychiatrist offered an injectable antipsychotic to a patient with schizophrenia. These visits were transcribed and analyzed by a team of linguists and social scientists. Results: Our primary finding is that, based on analyses of their language during the interview, psychiatrists presented LAI therapy in a negative light. Supporting this, 11 of 33 recommendations (33%) were accepted during the discussion, whereas in the postvisit interview, 27 of 28 patients (96%) who seemed to decline the initial recommendation said they actually would be willing to try LAI treatment. Conclusions: These data support a preliminary hypothesis that the relatively low use of injectable antipsychotic therapies in the United States relative to other parts of the world is not fully attributable to patient rejection of the injectable modality. Rather, psychiatrists' ambivalence regarding the value of LAIs may play a significant role in the perceived difficulty with patient acceptance of this recommendation. (c) Copyright 2015 Physicians Postgraduate Press, Inc.
引用
收藏
页码:684 / 690
页数:7
相关论文
共 50 条
  • [41] COMBINATION LONG-ACTING INJECTABLE ANTIPSYCHOTIC MEDICATION IN TREATMENT RESISTANT SCHIZOPHRENIA: A CASE SERIES
    Osunkoya, A.
    Thomas, N.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2023, 57 (01): : 189 - 189
  • [42] Preliminary results of a network meta-analysis on the efficacy of long-acting injectable antipsychotics in schizophrenia
    Medrano, R.
    Carranza, F.
    Saucedo, E.
    Guerrero, A.
    EUROPEAN PSYCHIATRY, 2021, 64 : S162 - S162
  • [43] SCHIZOPHRENIA PATIENT PERSISTENCE TO LONG-ACTING ANTIPSYCHOTIC THERAPY IN NEW ZEALAND
    Berney, K.
    Grant, A.
    Acar, M.
    Shaw, S.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 139 - 139
  • [44] ECONOMIC ANALYSIS OF PALIPERIDONE LONG-ACTING ACTING INJECTABLE FOR CHRONIC SCHIZOPHRENIA IN PORTUGAL
    Maia-Lopes, S.
    Van Impe, K.
    Goswami, P.
    Einarson, T. R.
    VALUE IN HEALTH, 2015, 18 (07) : A410 - A410
  • [45] Hospitalization Resource Utilization and Costs Among Medicaid Insured Patients With Schizophrenia With Different Treatment Durations of Long-Acting Injectable Antipsychotic Therapy
    Bera, Rimal
    Offord, Steve
    Zubek, Donna
    Lau, Gina
    Lin, Jay
    Karson, Craig
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (01) : 30 - 35
  • [46] Treatment journey of patients with schizophrenia from diagnosis to the successful implementation of treatment with a long-acting injectable antipsychotic agent
    Kane, J. M.
    Mychaskiw, M. A.
    Lim, S.
    Suett, M.
    Tian, M.
    Park, S.
    Rubio, J. M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S567 - S567
  • [47] Hospitalization and medication use in schizophrenia patients receiving risperidone long-acting injectable or oral atypical antipsychotic medication
    Chue, P.
    Lam, A.
    Chandra, K.
    Luong, D.
    Camacho, F.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S263 - S263
  • [48] Hospitalization and medication use in schizophrenia patients receiving risperidone long-acting injectable or oral atypical antipsychotic medication
    Chue, P
    Lam, A
    Chandra, K
    Luong, D
    Camacho, F
    VALUE IN HEALTH, 2005, 8 (06) : A202 - A202
  • [49] Real-World Effectiveness of Long-Acting Injectable and Oral Antipsychotic Agents in US Medicare Patients with Schizophrenia
    Li, Pengxiang
    Geng, Zhi
    Benson, Carmela
    Patel, Charmi
    Doshi, Jalpa A.
    ADVANCES IN THERAPY, 2025, 42 (02) : 1251 - 1264
  • [50] Long-Acting Injectable Antipsychotic Initiation in Child and Adolescent Patients with Psychiatric Disorders
    Sun, Christina
    Temelie, Andreea
    Goulding, Hannah
    Clark, Christine
    Yabs, Melanie
    Fabian, Tanya
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2025, 35 (02) : 80 - 86